Immunodeficiency Diseases
📧 Sign up to get email alerts when something new happens for Immunodeficiency Diseases.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-20EMA Authorised: Xolremdi (mavorixafor) — Norgine B.V.
Xolremdi (mavorixafor) has been authorised in the EU for primary immunodeficiency diseases by Norgine B.V. (orphan medicine).
-
EMA approval · 2026-07-07EMA Authorised: Xolremdi (mavorixafor) — Norgine B.V.
EMA authorised Xolremdi (mavorixafor) by Norgine B.V. for primary immunodeficiency diseases (orphan medicine).
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases [Phase 3]
Phase 3 trial evaluating pharmacokinetics, efficacy, tolerability, and safety of subcutaneous Newnorm immunoglobulin in patients with primar…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases [Phase 3]
This clinical trial update reports on the long-term safety study of TAK-881 in individuals with primary immunodeficiency diseases, currently…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency
A clinical trial update describes a study evaluating the efficacy of immunoglobulin and performing immune profiling in individuals with anti…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Biologics And Clinical Immunology Cohort at Sinai
A clinical trial update for the Biologics And Clinical Immunology Cohort at Mount Sinai. The study is currently recruiting to evaluate biolo…
-
EMA approval · 2026-02-11EMA Authorised: HyQvia (human normal immunoglobulin) — Baxalta Innovations GmbH
EMA authorised HyQvia, a subcutaneous immunoglobulin product with recombinant human hyaluronidase, from Baxalta Innovations GmbH for immunod…
-
CLINICAL_TRIALS trial_result · 2026-02-03Clinical Trial Update: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases [Phase 2, Phase 3]
This clinical trial update reports on how TAK-881 is processed by the body and its side effects in people with Primary immunodeficiency dise…
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: Study of BP-SCIG 20% in Patients With Primary Immunodeficiency (PID) [Phase 3]
This document provides an update on a Phase 3 clinical trial evaluating BP-SCIG 20% for primary immunodeficiency, with recruitment ongoing.
-
CLINICAL_TRIALS trial_result · 2025-12-08Clinical Trial Update: Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases [Phase 2]
A Phase 2 trial comparing treosulfan-based conditioning to busulfan-based conditioning in pediatric patients with non-malignant diseases has…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders [NA]
This clinical trial update describes an ex vivo evaluation of a JAK-inhibitor and a gene-therapy approach for JAK-STAT related disorders, cu…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy [NA]
This ClinicalTrials.gov entry describes a pediatric stem cell transplant and cellular therapy trial evaluating a family health communication…
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: Study of Populations at Risk of Developing Chronic Hepatitis Linked to Chronic Enteric Virus Infection in Patients With Primary Immunodeficiency and Secondary Humoral Deficiency
This clinical trial update indicates the study is currently recruiting to evaluate populations at risk of developing chronic hepatitis linke…
-
EMA approval · 2025-11-24EMA Authorised: Hizentra (human normal immunoglobulin (SCIg)) — CSL Behring GmbH
EMA authorised Hizentra, a subcutaneous immunoglobulin product, by CSL Behring, for immunologic deficiency syndromes related to primary immu…
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion [NA]
Clinical trial update from Baylor College of Medicine reports results for haploidentical hematopoietic cell transplantation using TCR alpha/…
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases [Phase 3]
A Phase 3 trial is evaluating the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous Newnorm human immunoglobulin in patie…
-
CLINICAL_TRIALS trial_result · 2025-09-15Clinical Trial Update: Primitive Immunodeficiency, Intrauterine Devices and Menstrual Hygiene Products
This clinical trial, sponsored by Assistance Publique - Hôpitaux de Paris, investigates intrauterine devices and menstrual hygiene products …
-
CLINICAL_TRIALS trial_result · 2025-07-31Clinical Trial Update: Evaluation of an IgG Deficiency Rapid Screening Test: A Performance Study With Primary Immunodeficiency (PID) Patients in Tunisia
A completed performance study evaluating an IgG deficiency rapid screening test in patients with primary immunodeficiency diseases in Tunisi…
-
CLINICAL_TRIALS trial_result · 2025-07-31Clinical Trial Update: Developing a Screening Tool for Primary Immunodeficiency Disease (PID) in Pakistan
A completed clinical trial update from PATH about developing a screening tool for primary immunodeficiency diseases in Pakistan.
-
CLINICAL_TRIALS trial_result · 2025-06-12Clinical Trial Update: Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients [Phase 3]
A Phase 3 clinical trial evaluating the efficacy, safety, and pharmacokinetics of Virchow IVIG in patients with primary immunodeficiency dis…
-
CLINICAL_TRIALS research · 2025-06-04Clinical Trial Update: Virtual Reality on Pain and Fear Levels of Children With Primary Immunodeficiency [NA]
This clinical trial investigates whether virtual reality can reduce pain and fear in children with primary immunodeficiency diseases. The st…
-
CLINICAL_TRIALS research · 2025-05-02Clinical Trial Update: Expanded Access to TAK-881 for Children and Teenagers With Primary Immunodeficiency Diseases in the USA
Expanded access for TAK-881 in pediatric patients with primary immunodeficiency diseases in the USA is now available.
-
CLINICAL_TRIALS research · 2024-10-21Clinical Trial Update: Inbon Errors of Immunity Attending Assiut University Children&Amp;#39;s Hospital: a Single Center Study
A single-center clinical trial from Assiut University Children’s Hospital investigating primary immunodeficiency diseases; the study is not …
-
CLINICAL_TRIALS research · 2024-07-25Clinical Trial Update: Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders [Phase 2]
Phase 2 clinical trial update describing a reduced-intensity conditioning regimen for patients with non-malignant hematologic disorders, inc…
-
CLINICAL_TRIALS trial_result · 2024-03-22Clinical Trial Update: A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID) [Phase 3]
Phase 3 trial update for subcutaneous immunoglobulin 20% (IGSC, 20%) in Japanese participants with primary immunodeficiency diseases complet…